Clinical Trial Update: Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial) [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial (EARLY-GENE) evaluating early candesartan treatment versus placebo in genetic carriers of dilated cardiomyopathy; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• Candesartan (candesartan)

Snippet

Sponsor: Cristina Avendaño Solá | Conditions: Cardiomyopathy, Dilated | Phase 3 | Status: RECRUITING